Triple negative breast cancer (TNBC) is associated with aggressive behaviour and poor prognosis, but has limited treatment options. To explore novel and effective therapies against TNBC, we retrospectively analyzed the efficacy of neoadjuvant intraarterial chemotherapy through the superior epigastric artery in the treatment of locally advanced TNBC. Fifty-one locally advanced TNBC patients who received this neoadjuvant therapy from Mar 2001 to Mar 2012 were included in this study. The superior epigastric artery was selected for cannulation to deliver chemotherapy drugs. The regimen for intra-arterial chemoinfusion consisted of 75 mg/m 2 epirubicin and 75 mg/m 2 docetaxel. Clinical and pathological tumor responses, disease free survival (DFS), overall survival (OS), and toxicity profiles were recorded and retrospectively analyzed. In 51 patients treated with neoadjuvant intra-arterial chemoinfusion through the superior epigastric artery, the overall response rate (ORR) was 84.3%; 16 patients achieved pathological complete response (pCR). Following surgical treatment and adjuvant chemotherapy, 5-year DFS and OS were 72.4% and 75.9%, respectively, in the study population. In addition, this neoadjuvant approach showed favorable toxicity profiles. Moreover, patients who achieved pCR showed a superior survival outcome compared with those who did not. Cox regression analysis indicated that Ki-67 expression is an independent predictor for DFS and OS. Our results suggest that intra-arterial chemotherapy through the superior epigastric artery has great therapeutic potential for the treatment of locally advanced TNBC. This approach merits further clinical evaluation and may become a novel therapeutic option for locally advanced TNBC.
Breast cancer is one of the most lethal diseases for women. It is a heterogeneous disease in which the presence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) signals can be used to construct molecular subtypes [1] [2] [3] . The subtype negative for ER, PR, and HER2 is defined as triple negative breast cancer (TNBC), which has a gene expression profile similar to basocellular breast cancer. However, TNBC is associated with aggressive biological behavior and poor prognosis [4] [5] [6] . It can lead to an increased risk of recurrence and visceral metastasis, as well as a higher mortality rate. Moreover, treatment options for TNBC are quite limited due to the absence of targeting receptors [7, 8] .
In recent years, neoadjuvant chemotherapy (also called primary or preoperative chemotherapy) has been increasingly used in patients with TNBC. The aim of neoadjuvant treatment is to reduce the size of unresectable tumors, thus allowing surgery to become an option for these patients [9] . Additionally, for patients with resectable tumors, neoadjuvant treatment decreases the need for mastectomy and increases the likelihood of breast conservation [10] .
A number of studies have demonstrated that neoadjuvant chemotherapy is more beneficial for TNBC than for non-TNBC tumors [11] . For example, Liedtke et al. [12] reported that the rates of pathological complete response (pCR) were significantly higher with neoadjuvant treatment in patients with TNBC than in those with non-TNBC. Additionally, researchers found that in TNBC patients with pCR, neoadjuvant treatment is associated with improved overall survival (OS) as compared with adjuvant treatment [13] . Therefore, neoadjuvant chemotherapy has been accepted as a reliable treatment option for TNBC, especially in the locally advanced stages [14] [15] [16] .
Intra-arterial infusion chemotherapy has been used as a neoadjuvant treatment for breast cancer since the 1960s [17, 18] . In this setting, chemotherapeutics can effectively reach the tumor tissue via cannulation of the dominant artery supplying the breast (e.g. the subscapular artery, or the lateral or internal thoracic arteries), and achieve a high local drug concentration, leading to enhanced anticancer effects as compared to conventional intravenous infusion [19, 20] . Several studies have demonstrated the effectiveness of intra-arterial infusion in the treatment of breast cancer, with response rates ranging from 77.3% to 90% [21, 22] . Nevertheless, as far as we know, the majority of current cannulation procedures for intra-arterial chemoinfusion are performed through the femoral artery to the subclavian artery, which can cause the chemotherapeutic drugs to flow into the ipsilateral upper extremity, leading to severe complications such as atrophy and disability of the ipsilateral upper extremity [19] . Therefore, the cannulation procedure still needs to be improved in order to minimize the risk of complications and sequelae related to intra-arterial chemotherapy.
The superior epigastric artery, a terminal branch of the internal thoracic artery, is located outside the thoracic cavity and supplies the upper anterior part of the abdominal wall [23] . This artery is superficial as compared to the internal thoracic artery, and may represent an ideal potential target artery for intra-arterial chemoinfusion for breast cancer [24] . To date, however, there are few reports on the efficacy of intra-arterial chemoinfusion through this artery, especially in the treatment of locally advanced TNBC. In our clinical practice, we began cannulating the superior epigastric artery to perform intraarterial infusion in breast cancer patients in 2001. The present study was carried out in order to retrospectively evaluate the efficacy of this approach for patients with locally advanced TNBC.
Patients and methods
Setting and inclusion/exclusion criteria. In this study, we retrospectively reviewed a database of breast cancer patients who underwent intra-arterial neoadjuvant chemotherapy through the superior epigastric artery from Mar 2001 to Mar 2012 in the authors' institution. The study protocol complies with the principles of the Declaration of Helsinki and was approved by the institutional review board.
In order to ensure the quality of this retrospective study, strict inclusion and exclusion criteria were applied. Patients were included if they met the following criteria: (1) age ≥ 18 years old; (2) female with newly-diagnosed primary, unilateral, non-metastasized breast cancer; (3) histologically confirmed TNBC; (4) histologically conformed locally advanced breast cancer (T3-4 any NM0 or any TN2M0) according to the American Joint Committee on Cancer (AJCC) staging manual (7 th edition); (4) adequate baseline hematologic, hepatic and renal functions; (5) no other malignant tumors; and (6) having detailed clinical and follow-up data available for review. Exclusion criteria were age less than 18 years, pregnancy, or breast-feeding.
Surgical procedures for intra-arterial chemoinfusion. The superior epigastric artery ipsilateral to the lesion was cannulated for intra-arterial chemoinfusion. In brief, a 6-cm paramedian incision was made in the epigastrium, and dissection was carried down through the subcutaneous tissue. Then, the anterior layers of the rectus sheath were opened and approximately 1.5 to 2.0 cm of the superior epigastric artery was exposed. After distal ligation, a catheter (4F or 5F Cobra catheter (Cook Corporation, Bloomington, IN, USA)) was proximally inserted into the superior epigastric artery and advanced about 18 -20 cm. Afterwards, 2 ml methylene blue solution (1%, weight/volume) was injected through the catheter to optimize catheter advancement according to the extent of the staining. Complete staining of the skin overlying tumor lesions indicated the optimal position for the catheter. After the catheter was fixated, chemotherapeutic drugs were infused through the catheter using an infusion pump for a minimum of 20 min. The regimen for intra-arterial chemoinfusion consisted of 75 mg/m 2 epirubicin and 75 mg/m 2 docetaxel in 50 ml of normal saline. After the infusion was completed, the catheter was removed and the distal end of the superior epigastric artery was ligated in order to achieve a high drug concentration in the tumor and prevent leakage of the drugs.
Intra-arterial chemoinfusion was performed once every three weeks. Two weeks after the first infusion, primary lesions and involved lymph nodes were evaluated by ultrasound and magnetic resonance imaging (MRI) in all patients. Surgery (modified radical mastectomy or breast-conserving surgery) was carried out if there was both a significant improvement in the involvement of skin and muscle tissue and the primary lesion and regional lymph nodes had shrunken considerably in volume. Otherwise, patients were assigned to undergo another cycle of intra-arterial chemoinfusion. After surgery, adjuvant intravenous chemotherapy was administered for up to six cycles using the same regimen as for intra-arterial chemotherapy.
Immunohistochemical evaluation of Ki-67. Ki-67 expression in tumor tissues was detected by immunohistochemistry (IHC). Briefly, core needle biopsies (≥ 3 representative specimens) were performed in all patients. The collected specimens were embedded in paraffin and sliced to 4 μm in thickness, according to the routine method. Then, the prepared sections were fixed in 10% neutral formaldehyde solution and incubated with Ki-67 primary antibody after antigen retrieval (dilution: 1:100) (Boster Co. Ltd., Wuhan, China). Afterwards, sections were treated with a horseradish peroxidase (HRP)-labeled secondary antibody and diaminobenzidine (DAB) kit (Boster Co. Ltd.), and counter-stained with hematoxylin.
For each patient, five high-power fields (40×) containing at least 1000 tumor cells were randomly selected for semiquantitative IHC analysis. Cells with immunostaining in the nucleus were defined as Ki-67-positive cells. The percentage of Ki-67-positive cells was calculated by counting the number of Ki-67-positive cells and the total number of cells. A Ki-67 expression cut-off value of 20% was defined according to previous literature [25, 26] .
Tumor response and toxicity assessment. Clinical tumor responses to intra-arterial chemotherapy were assessed based on ultrasound and MRI examinations according to the response evaluation criteria for solid tumors (RECIST 1.1) [27] . A pathological complete response (pCR) was defined as the absence of residual invasive cancer in both the breast tissue and regional lymph nodes of the surgical specimen.
The toxicity of intra-arterial chemoinfusion was assessed at each cycle from the first day of the treatment until the day before surgery. Toxicity was monitored by routine physical examination, laboratory tests, and electrocardiogram (ECG); and classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.
Follow-up. For all patients, follow-up was conducted every 3 to 4 months for the first 2 years, then every 6 months thereafter. Disease free survival (DFS) was measured from the date of diagnosis to the date of last follow-up, disease relapse (i.e. local and regional recurrence, distant metastases, or occurrence of secondary malignant neoplasms), or death. OS was calculated as the period from the date of diagnosis to the date of last follow-up or death.
Statistical analysis. All statistical analyses were performed using SPSS 13.0 software (SPSS Inc., Chicago, IL). Categorical data are expressed as counts and percentages. Continuous data are presented as means ± standard deviations (SD). For survival data, Kaplan-Meier survival curves were plotted, and statistical differences were analyzed using the log-rank test. Univariate and multivariate logistic regression were performed to analyze the impact of the variables on the response rate of pCR. A Cox regression model was used to analyze the impact of the variables on patient survival. Hazard ratios (HR) were presented with their 95% confidence intervals (95% CI). A value of P < 0.05 was considered statistically significant (two-tailed).
Results

Demographic characteristics of patients.
A total of 51 locally advanced TNBC patients who received intra-arterial chemoinfusion were eligible for this retrospective analysis during the study period. Their demographic characteristics are presented in Table 1 . Forty-four patients (86.3%) were diagnosed with T3 or T4 diseases, and 48 (94.1%) were classified as AJCC stage III diseases. The mean tumor size was 9.7 cm in diameter. Skin and/or chest muscle involvement was seen in 14 patients (27.5%), and axillary lymph node enlargement was found in 37 patients (72.5%). Additionally, Ki-67 expression < 20% was seen in 24 patients (47.1%).
Tumor response and toxicity assessment. All patients received surgical treatment after one cycle of intra-arterial chemoinfusion and were qualified for clinical and pathological response assessment. Tumor response results are summarized in Table 2 . The overall response rate (ORR) and disease control rate (DCR) were 84.3% and 98.0%, respectively. After intraarterial treatment, the mean tumor size of patients was 3.6 cm in diameter, which was significantly reduced as compared to pretreatment values. Additionally, symptoms in patients with skin and/or chest muscle involvement or with axillary lymph node enlargement showed improvements after intra-arterial chemoinfusion. Thirty-five patients received modified radical 27 (52.9) a Data are presented as mean ± SD Abbreviations: AJCC, American Joint Committee on Cancer mastectomy, while the rest received breast-conserving surgery. All surgeries were performed by experienced surgeons. The success rate of surgical resection was 100%, and no patients developed severe intra-or post-operative complications. After surgery, 16 patients achieved pCR. Both univariate and multivariate analysis showed that Ki-67 expression was an independent predictor for pCR (Tables 3 and 4 ), indicating that patients with high Ki-67 expression (≥ 20%) were more sensitive to intra-arterial chemotherapy (representative IHC images of high and low Ki-67 expression are shown in Figure 1 )
The toxicity profiles of intra-arterial chemoinfusion are listed in Table 5 . It should be noted that skin ulceration was the most frequent toxicity found in this study (21.6%, 11 out of 51). Two patients (3.9%) even experienced grade 3/4 skin ulcerations, which were resolved by treatment with appropriate topical care. Other toxicities included gastrointestinal, hematologic, and cardiac disorders. However, these adverse events were mild (grade 1/2) and well-tolerated by patients, or were able to be controlled after 3 -5 days of symptomatic treatment.
Survival outcomes. After surgery, 32 patients received three cycles of intravenous adjuvant chemotherapy, 14 patients received four cycles, and 5 patients received five cycles. After a median follow-up of 100.6 months (33.6 -162.7 months), 13 patients (25.5%) died of breast cancer-related causes, all of which had stage III tumors. Kaplan-Meier curves for DFS and OS are shown in Figure 2 . Five-year DFS and OS rates were 72.4% and 75.9%, respectively. Moreover, patients who achieved pCR showed a superior survival outcome compared with those who did not. In the pCR population, recurrence 
Discussion
This study was a single center, retrospective study with the purpose of investigating the efficacy of intra-arterial neoadjuvant chemotherapy through the superior epigastric artery in the treatment of locally advanced TNBC. For the 51 patients treated using this approach, the ORR was 84.3% (33.3% CR and 51.0% PR); 16 patients achieved pCR. Following surgical treatment and adjuvant chemotherapy, 5-year DFS and OS in the study population were 72.4% and 75.9%, respectively. In addition, intra-arterial chemotherapy through the superior epigastric artery showed favorable toxicity profiles. Taken together, our results suggest that this neoadjuvant approach has great therapeutic potential for the treatment of locally advanced TNBC.
As compared with other subtypes of breast cancer, treatment options for TNBC are limited due to the absence of drug-targetable receptors [7, 8] . Nevertheless, a number of studies have demonstrated that TNBC responds well to cytotoxic chemotherapy, commonly having higher pCR rates than those found in other breast cancer subtypes [25] . Neoadjuvant chemotherapy is a well-established approach to the treatment of locally advanced TNBC, which reduces the size of unresectable tumors, thereby allowing surgical intervention to be performed [28] . In the neoadjuvant setting, chemotherapeutic agents are conventionally administered by intravenous infusion. Despite impressive response rates, however, conventional neoadjuvant therapy is associated with high local recurrence rates (up to 38%) and high toxicity profiles [29] . In addition, researchers reported that a high proportion of patients with locally advanced TNBC had poor prognoses after conventional neoadjuvant therapy due to failure to control local micrometastases of the tumor [30] . Therefore, in order to gain effective local control of micrometastasis, regional chemotherapy via intra-arterial infusion has been developed and evaluated in a number of clinical studies [9] . Table 6 summarizes the recent published results (within 10 years) regarding the outcomes of intra-arterial chemoinfusion in the treatment of breast cancer.
The major advantage of intra-arterial chemotherapy lies in the fact that it can achieve a relatively high drug concentration and retention in primary tumor tissues and involved lymph nodes, consequently improving anti-cancer efficacy and reducing the occurrence of side effects in normal tissues [31] . Additionally, in this setting, regionally administered chemotherapeutic agents can return to tumor tissues through blood 
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Skin ulceration 11 2 circulation, thus exerting a "second-hit" impact on tumors. In this study, intra-arterial chemoinfusion through the superior epigastric artery achieved an ORR of 84.3% and a pCR rate of 31.3%, which are similar or even superior to the effects seen in standard intravenous neoadjuvant chemotherapy or intraarterial chemoinfusion through the femoral artery [19, 22, 32] (Table 6 ). Furthermore, long-term follow-up data showed that 5-year DFS and OS were 72.4% and 75.9%, respectively, in the study population. Collectively, these data, at least in part, reflect the effectiveness of this intra-arterial therapy in controlling locally advanced TNBC. Accumulating evidence from a series of clinical studies reveals that pCR is a predictive marker for clinical response, recurrence, and survival in TNBC patients [33, 34] . Consistently, in our study, survival analysis showed that patients who achieved pCR showed better DFS and OS rates than those who did not. However, it should be noted that pCR was defined as lacking any residual disease in both the breast tissue and axillary lymph nodes; otherwise, significant predictive errors may occur. In addition, IHC analysis indicated a significant association between Ki-67 expression in tumor tissues and the occurrence of pCR. Ki-67, initially identified by Gerdes et al [35] , is a nuclear protein associated with cell proliferation. Although there is still some debate, many studies have demonstrated the predictive value of Ki-67 regarding responsiveness to chemotherapy in breast cancer [36, 37] . Particularly, Fasching et al. [38] have reported that Ki67 serves as an independent predictor for pCR in a group of breast cancer patients receiving neoadjuvant treatment. In accordance with these findings, the present study also found that when patients were treated with intra-arterial chemotherapy through the superior epigastric artery, most cases achieving pCR had a high level of Ki-67 expression. This may be attributed to the fact that high Ki67 expression generally reflects increased proliferation, whereas breast cancer cells with a high proliferation rate are usually sensitive to chemotherapy [39] . Additionally, Cox regression analysis showed that Ki-67 expression ≥ 20% was an independent predictor for DFS and OS. Taken together, these results suggest that Ki-67 expression can also be used as an independent factor for predicting prognoses of locally advanced TNBC patients treated using this neoadjuvant approach.
With regard to the toxicity profile, low incidence of gastrointestinal, hematological, and cardiac toxicity was observed using intra-arterial chemoinfusion through the superior epigastric artery. Moreover, as compared with other intra-arterial chemoinfusion procedures, cannulation through the superior epigastric artery can help to prevent serious upper extremity complications caused by leakage of chemotherapeutic drugs into the ipsilateral upper extremity. Nevertheless, it should be noted that skin ulceration was the most frequent toxicity related to this neoadjuvant chemoinfusion, which may be attributed to accidental leakage of epirubicin into the surrounding tissue. Hence, the surgical procedures, as well as treatment regimens such as dosing and schedule, should be further optimized in order to minimize treatment-related toxicity.
Several limitations of the present study should be addressed. The main limitation is its retrospective nature, which may have introduced inherent selection biases. Another limitation is the small population size and single ethnicity, which may limit the generalizability of the findings of this study. In addition, the lack of a control group limits interpretation of the results and prevents us from drawing any firm conclusions.
In summary, our data demonstrate the significant efficacy and safety of intra-arterial neoadjuvant chemotherapy through the superior epigastric artery in the treatment of newly-diagnosed locally advanced TNBC. This study provides supportive evidence that this neoadjuvant approach has great therapeutic potential for locally advanced TNBC and is most likely suitable for cases with higher Ki-67 expression. Thus, this treatment 
